Soligenix Inc (SNGX)

$3.14 +0.01 (0.32%)
Market Cap 13.41M
Revenue (ttm) 120,000.00
Net Income (ttm) -8.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,891.67%
Debt to Equity Ratio 0.00
Volume 357,300
Avg Vol 13,870,172
Day's Range N/A - N/A
Shares Out 4.29M
Stochastic %K 17%
Beta 1.95
Analysts Strong Buy
Price Target $22.50

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 538 8200
Fax: 609 452 6467
Address:
29 Emmons Drive, Suite B-10, Princeton, United States
ODucks
ODucks Aug. 27 at 5:52 AM
$SNGX One of the biggest red flags here is that they still haven’t made a single dollar yet.
0 · Reply
belikemike7
belikemike7 Aug. 26 at 7:33 PM
$SNGX SOLD. Looks like it wants to close the $2.87 gap before going back to $4+. I have buy orders in the $2.80 range
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 26 at 7:28 PM
$SNGX Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline https://ibn.fm/RTss7
0 · Reply
JeanBets
JeanBets Aug. 26 at 1:57 PM
$SNGX 🦍⭐️⭐️💰
0 · Reply
cartiersockss
cartiersockss Aug. 25 at 8:20 PM
$SNGX @Sw1ngb0t how you feelin
2 · Reply
wehavethem62
wehavethem62 Aug. 25 at 7:42 PM
$SNGX
0 · Reply
JeanBets
JeanBets Aug. 25 at 7:26 PM
$SNGX 🦍🦍💎💎💰
0 · Reply
ShadowSnake
ShadowSnake Aug. 25 at 6:33 PM
$SNGX damn this was doing so good too… management needs to buy back shares
0 · Reply
ODucks
ODucks Aug. 25 at 4:41 PM
$SNGX $0 in rev.
0 · Reply
JeanBets
JeanBets Aug. 25 at 2:45 PM
$SNGX 🦍💎💰
0 · Reply
Latest News on SNGX
Why Is Soligenix Stock Soaring On Monday?

Aug 18, 2025, 1:03 PM EDT - 8 days ago

Why Is Soligenix Stock Soaring On Monday?

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 18, 2025, 7:30 AM EDT - 8 days ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Aug 14, 2025, 7:30 AM EDT - 12 days ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Aug 8, 2025, 8:30 AM EDT - 18 days ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 31, 2025, 7:30 AM EDT - 26 days ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 8, 2025, 7:30 AM EDT - 7 weeks ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jul 1, 2025, 7:30 AM EDT - 2 months ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

Jun 6, 2025, 9:37 AM EDT - 2 months ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

May 9, 2025, 7:30 AM EDT - 3 months ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Apr 14, 2025, 7:30 AM EDT - 4 months ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 8:30 AM EDT - 5 months ago

IBN Initiates Coverage of Soligenix Inc.

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 25, 2025, 7:30 AM EDT - 5 months ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 21, 2025, 7:30 AM EDT - 5 months ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Mar 6, 2025, 7:30 AM EST - 6 months ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Soligenix to Present at BIO CEO & Investor Conference

Feb 4, 2025, 7:30 AM EST - 7 months ago

Soligenix to Present at BIO CEO & Investor Conference

Soligenix to Present at Upcoming Investor Conferences

Jan 16, 2025, 7:30 AM EST - 7 months ago

Soligenix to Present at Upcoming Investor Conferences

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Jan 14, 2025, 7:30 AM EST - 8 months ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 9 months ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Dec 2, 2024, 7:30 AM EST - 9 months ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 19, 2024, 7:30 AM EST - 10 months ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 15, 2024, 7:30 AM EST - 10 months ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 14, 2024, 7:15 AM EST - 10 months ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Nov 8, 2024, 7:30 AM EST - 10 months ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 22, 2024, 7:30 AM EDT - 11 months ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Soligenix Invited to Present at Upcoming Investor Conferences

Oct 16, 2024, 7:30 AM EDT - 11 months ago

Soligenix Invited to Present at Upcoming Investor Conferences

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Oct 7, 2024, 7:30 AM EDT - 11 months ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix Announces Partnership with Sterling Pharma Solutions

Oct 3, 2024, 7:30 AM EDT - 11 months ago

Soligenix Announces Partnership with Sterling Pharma Solutions

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Sep 20, 2024, 9:00 AM EDT - 1 year ago

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 16, 2024, 9:00 AM EDT - 1 year ago

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

AREC

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Jul 15, 2024, 10:16 AM EDT - 1 year ago

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Soligenix stock rallies 400% on positive HyBryte trial results

Jul 9, 2024, 12:46 PM EDT - 1 year ago

Soligenix stock rallies 400% on positive HyBryte trial results

Crude Oil Down 1%; Soligenix Shares Surge

Jul 9, 2024, 12:11 PM EDT - 1 year ago

Crude Oil Down 1%; Soligenix Shares Surge

Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

Jul 9, 2024, 11:38 AM EDT - 1 year ago

Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

Jun 14, 2024, 7:30 AM EDT - 1 year ago

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jun 7, 2024, 9:00 AM EDT - 1 year ago

Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

STSS

Soligenix Announces Reverse Stock Split

May 31, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Reverse Stock Split

Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting

May 29, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

May 24, 2024, 7:30 AM EDT - 1 year ago

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split

May 23, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

May 21, 2024, 7:30 AM EDT - 1 year ago

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting

May 20, 2024, 7:30 AM EDT - 1 year ago

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

May 16, 2024, 7:30 AM EDT - 1 year ago

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results

May 10, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results

Soligenix to Present at Upcoming Conferences

May 6, 2024, 7:30 AM EDT - 1 year ago

Soligenix to Present at Upcoming Conferences

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

Apr 25, 2024, 7:30 AM EDT - 1 year ago

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

ODucks
ODucks Aug. 27 at 5:52 AM
$SNGX One of the biggest red flags here is that they still haven’t made a single dollar yet.
0 · Reply
belikemike7
belikemike7 Aug. 26 at 7:33 PM
$SNGX SOLD. Looks like it wants to close the $2.87 gap before going back to $4+. I have buy orders in the $2.80 range
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 26 at 7:28 PM
$SNGX Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline https://ibn.fm/RTss7
0 · Reply
JeanBets
JeanBets Aug. 26 at 1:57 PM
$SNGX 🦍⭐️⭐️💰
0 · Reply
cartiersockss
cartiersockss Aug. 25 at 8:20 PM
$SNGX @Sw1ngb0t how you feelin
2 · Reply
wehavethem62
wehavethem62 Aug. 25 at 7:42 PM
$SNGX
0 · Reply
JeanBets
JeanBets Aug. 25 at 7:26 PM
$SNGX 🦍🦍💎💎💰
0 · Reply
ShadowSnake
ShadowSnake Aug. 25 at 6:33 PM
$SNGX damn this was doing so good too… management needs to buy back shares
0 · Reply
ODucks
ODucks Aug. 25 at 4:41 PM
$SNGX $0 in rev.
0 · Reply
JeanBets
JeanBets Aug. 25 at 2:45 PM
$SNGX 🦍💎💰
0 · Reply
belikemike7
belikemike7 Aug. 25 at 1:47 PM
$SNGX The time for a reversal is drawing near! If you want the price to move up you got to buy the ASK! let's go Bulls!
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 25 at 1:04 AM
Money Monday Watchlist Pt. 17 $VVPR $SNOA $SNGX $KULR $CLOV This Week Might Be Life Changing 💸
0 · Reply
StockSenseiTrendTraders
StockSenseiTrendTraders Aug. 24 at 4:27 PM
🔥 Weekly Recap (8/18–8/22) 🔥 1️⃣ $THAR 🚀 +282.17% 🔹 Entry Alert: 1.57 🔹 High: 6.00 2️⃣ $APM 🚀 +145.00% 🔹 Entry Alert: 2.00 🔹 High: 4.90 3️⃣ $PTIX 🚀 +72.22% 🔹 Entry Alert: 3.60 🔹 High: 6.20 4️⃣ $SNGX 🚀 +63.52% 🔹 Entry Alert: 3.81 🔹 High: 6.23 5️⃣ $GXAI 🚀 +35.00% 🔹 Entry Alert: 1.80 🔹 High: 2.43 📊 2025 Performance Highlights 🏆 Wins: 929 ❌ Losses: 67 🚀 Gain Potential: +43,054% ✨ Avg Gain/Winning Alert: 46.34%
1 · Reply
HopehelpsU
HopehelpsU Aug. 22 at 8:50 PM
$SNGX I wonder how many wish they had a second chance to sell at $6 the other day? Greed is a maddafacka.
1 · Reply
Black_Socrates
Black_Socrates Aug. 22 at 7:55 PM
$SNGX
1 · Reply
Black_Socrates
Black_Socrates Aug. 22 at 7:55 PM
$SNGX
0 · Reply
darnellstockpile
darnellstockpile Aug. 22 at 7:49 PM
$SNGX stupid thing went up 600% just so they can so bleed it to 0 🤣🤣🤣🤣🤣🤣🤣 short borrow rate 500% is because its guaranteed odds on scam here
0 · Reply
darnellstockpile
darnellstockpile Aug. 22 at 7:45 PM
$SNGX closing red for the rest of the year 😂😂😂😂😂😂
1 · Reply
Buenperrito
Buenperrito Aug. 22 at 7:34 PM
$SNGX 👀
0 · Reply
billsmall
billsmall Aug. 22 at 7:26 PM
$SNGX 2 parts AI Overview To stop your shares from being shorted in a margin account, you must remove your shares from your margin account by moving them to a cash account or by placing a "buy to cover" order for any existing short positions you may have. You can also try to opt out of securities lending programs through your broker, which prevents your shares from being loaned out to short sellers. 1. Close Existing Short Positions Short covering: If you have already opened a short position, you need to buy back the shares to close the position. You can do this by placing a "buy to cover" order with your broker. 2. Move Shares Out of the Margin Account Transfer to a cash account: You can typically transfer your shares from the margin account to a standard cash account within your brokerage. This will prevent your broker from lending out those specific shares. 3. Opt Out of Securities Lending Programs Continued -
1 · Reply
Black_Socrates
Black_Socrates Aug. 22 at 7:11 PM
$SNGX I just put my shares on sell with high ceiling like $10/share sothat my broker not to be able to use it for shorting. It creates scarcity for sure. Just an opinion.
1 · Reply
billsmall
billsmall Aug. 22 at 6:43 PM
$SNGX Retail needs to eat those 8k avail shares up so the shorts have to carry this over the weekend. This would be the perfect little micro cap to run hard AH on a Friday with 500+% borrowing fees. Either way have a great weekend all.
0 · Reply